Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age

Journal of Clinical Virology

Volumn 59, Issue 2, 2014, Pages 104-108

  Cuschieri, Kate ^a   Cubie, Heather ^b   Graham, Catriona ^c   Rowan, Jennifer ^b   Hardie, Alison ^a   Horne, Andrew ^b   Earle, Camille Busby ^c   Bailey, Andrew ^d   Crosbie, Emma J ^e   Kitchener, Henry ^e  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Queen's Medical Research Institute   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cervical screening; Clinical performance; Diagnostics; HPV

Indexed keywords

VIRUS DNA; VIRUS RNA;

ADULT; APTIMA HUMAN PAPILLOMAVIRUS ASSAY; ARTICLE; ASSAY; COLPOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOLOGY; HUMAN; HYBRID CAPTURE 2 TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; YOUNG ADULT;

AHPV; APTIMA HPV TEST; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVICAL SCREENING; CIN; CLINICAL-PERFORMANCE; DIAGNOSTICS; HC2; HPV; HUMAN PAPILLOMAVIRUS; HYBRID CAPTURE 2 TEST;

ADULT; COLPOSCOPY; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84892998904     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.12.001     Document Type: Article

References (11)

1. Poljak M., Kocjan B.J. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010, 10:1139-1162.
2. Arbyn M., Roelens J., Cuschieri K., Cuzick J., Szarewski A., Ratnam S., et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 2012, 132:101-108.
3. Sørbye S.W., Arbyn M., Fismen S., Gutteberg T.J., Mortensen E.S. Triage of women with low-grade cervical lesions - HPV mRNA testing versus repeat cytology. PLoS ONE 2011, 6(8):e24083.
4. Sargent A., Bailey A., Turner A., Almonte M., Gilham C., Baysson H., et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010, 48:554-558.
5. Rebolj M., Bonde J., Njor S.H., Lynge E. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. Br Med J 2011, 342:d275.
6. Almonte M., Murillo R., Sánchez G.I., Jerónimo J., Salmerón J., Ferreccio C., et al. New paradigms and challenges in cervical cancer prevention and control in Latin America. Salud Publ Mex 2010, 52:544-559.
7. Altman D.G. Practical statistics for medical research 1991, Chapman & Hall, London.
8. Stoler M.H., Wright T.C., Cuzick J., Dockter J., Reid, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol 2013, 208. 144.e1-e8.
9. Cuschieri K.S., Cubie H.A., Whitley M.W., Seagar A.L., Arends M.J., Moore C., et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004, 57:68-72.
10. Bulkmans N.W., Rozendaal L., Snijders P.J., Voorhorst F.J., Boeke A.J., Zandwijken G.R., et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004, 110(May (1)):94-101.
11. Arbyn M., Roelens J., Simoens C., Buntinx F., Paraskevaidis E., Martin-Hirsch P.P., et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev 2013, 3(March):CD008054.